Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Willemien C. Menke-van der Houven van Oordt"'
Autor:
Jorianne Boers, Bertha Eisses, Mieke C. Zwager, Jasper J. L. van Geel, Frederike Bensch, Erik F. J. de Vries, Geke A. P. Hospers, Andor W. J. M. Glaudemans, Adrienne H. Brouwers, Martijn A. M. den Dekker, Sjoerd G. Elias, Evelien J. M. Kuip, Carla M. L. van Herpen, Agnes Jager, Astrid A. M. van der Veldt, Daniela E. Oprea-Lager, Elisabeth G. E. de Vries, Bert van der Vegt, Willemien C. Menke-van der Houven van Oordt, Carolina P. Schröder
Publikováno v:
Diagnostics, Vol 14, Iss 4, p 416 (2024)
Background: In metastatic breast cancer (MBC), [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [18F]FDG
Externí odkaz:
https://doaj.org/article/0281d22a7a0341db971fa3d7f507270b
Autor:
Ananthi Somasundaram, David Vállez García, Elisabeth Pfaehler, Yvonne W. S. Jauw, Josée M. Zijlstra, Guus A. M. S. van Dongen, Willemien C. Menke-van der Houven van Oordt, Marc C. Huisman, Elisabeth G. E. de Vries, Ronald Boellaard
Publikováno v:
EJNMMI Physics, Vol 9, Iss 1, Pp 1-13 (2022)
Abstract Purpose Low photon count in 89Zr-Immuno-PET results in images with a low signal-to-noise ratio (SNR). Since PET radiomics are sensitive to noise, this study focuses on the impact of noise on radiomic features from 89Zr-Immuno-PET clinical im
Externí odkaz:
https://doaj.org/article/e68e45dee393427aba60c8fc28f050d3
Autor:
Manouk K. Bos, Sarah R. Verhoeff, Sjoukje F. Oosting, Willemien C. Menke-van der Houven van Oordt, Ruben G. Boers, Joachim B. Boers, Joost Gribnau, John W. M. Martens, Stefan Sleijfer, Carla M. L. van Herpen, Saskia M. Wilting
Publikováno v:
Cancers, Vol 15, Iss 5, p 1374 (2023)
According to the current guidelines, watchful waiting (WW) is a feasible option for patients with good or intermediate prognosis renal-cell carcinoma (RCC). However, some patients rapidly progress during WW, requiring the initiation of treatment. Her
Externí odkaz:
https://doaj.org/article/cbabc4b832614067b0099dc4352b4ac8
Autor:
Bart M. de Vries, Sandeep S. V. Golla, Gerben J. C. Zwezerijnen, Otto S. Hoekstra, Yvonne W. S. Jauw, Marc C. Huisman, Guus A. M. S. van Dongen, Willemien C. Menke-van der Houven van Oordt, Josée J. M. Zijlstra-Baalbergen, Liesbet Mesotten, Ronald Boellaard, Maqsood Yaqub
Publikováno v:
Diagnostics, Vol 12, Iss 3, p 596 (2022)
Acquisition time and injected activity of 18F-fluorodeoxyglucose (18F-FDG) PET should ideally be reduced. However, this decreases the signal-to-noise ratio (SNR), which impairs the diagnostic value of these PET scans. In addition, 89Zr-antibody PET i
Externí odkaz:
https://doaj.org/article/a126295b2b554a6f80b62a95d68b22e0
Autor:
Joeri A. J. Douma, Laurien M. Buffart, Ramy Sedhom, Mariette Labots, Willemien C. Menke-van der Houven van Oordt, Mikkjal Skardhamar, Anthony De Felice, Esther Lee, Divya Dharmaraj, Nilofer S. Azad, Michael A. Carducci, Henk M. W. Verheul
Publikováno v:
Cancers, Vol 13, Iss 10, p 2304 (2021)
Despite stringent eligibility criteria for trial participation, early discontinuation often occurs in phase I trials. To better identify patients unlikely to benefit from phase I trials, we investigated predictors for early trial discontinuation. Dat
Externí odkaz:
https://doaj.org/article/e55abde13f614c96a89f06257384fd08
Autor:
Jasper J L, van Geel, Jorianne, Boers, Sjoerd G, Elias, Andor W J M, Glaudemans, Erik F J, de Vries, Geke A P, Hospers, Michel, van Kruchten, Evelien J M, Kuip, Agnes, Jager, Willemien C, Menke-van der Houven van Oordt, Bert, van der Vegt, Elisabeth G E, de Vries, Carolina P, Schröder
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(31)
Determining the estrogen receptor (ER) status is essential in metastatic breast cancer (MBC) management. Whole-body ER imaging with 16α-[In a prospective multicenter trial, 200 patients with newly diagnosed MBC underwent extensive workup including m
Autor:
Ananthi Somasundaram, David Vállez García, Elisabeth Pfaehler, Yvonne W. S. Jauw, Josée M. Zijlstra, Guus A. M. S. van Dongen, Willemien C. Menke-van der Houven van Oordt, Marc C. Huisman, Elisabeth G. E. de Vries, Ronald Boellaard
Publikováno v:
EJNMMI PHYSICS, 9(1):16. Springer International Publishing AG
Somasundaram, A, Vállez García, D, Pfaehler, E, Jauw, Y W S, Zijlstra, J M, van Dongen, G A M S, Menke-van der Houven van Oordt, W C, Huisman, M C, de Vries, E G E & Boellaard, R 2022, ' Noise sensitivity of Zr-89-Immuno-PET radiomics based on count-reduced clinical images ', EJNMMI PHYSICS, vol. 9, no. 1, 16, pp. 16 . https://doi.org/10.1186/s40658-022-00444-4
EJNMMI physics, 9(1):16. SpringerOpen
EJNMMI PHYSICS, 9(1). Springer International Publishing AG
Somasundaram, A, Vállez García, D, Pfaehler, E, Jauw, Y W S, Zijlstra, J M, van Dongen, G A M S, Menke-van der Houven van Oordt, W C, Huisman, M C, de Vries, E G E & Boellaard, R 2022, ' Noise sensitivity of Zr-89-Immuno-PET radiomics based on count-reduced clinical images ', EJNMMI PHYSICS, vol. 9, no. 1, 16, pp. 16 . https://doi.org/10.1186/s40658-022-00444-4
EJNMMI physics, 9(1):16. SpringerOpen
EJNMMI PHYSICS, 9(1). Springer International Publishing AG
Purpose Low photon count in 89Zr-Immuno-PET results in images with a low signal-to-noise ratio (SNR). Since PET radiomics are sensitive to noise, this study focuses on the impact of noise on radiomic features from 89Zr-Immuno-PET clinical images. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fe2083a6ec112dfe0927dbdb82f94a4
https://research.vumc.nl/en/publications/035214d0-d658-452d-a0f1-281ec67aaeb3
https://research.vumc.nl/en/publications/035214d0-d658-452d-a0f1-281ec67aaeb3
Autor:
Ananthi, Somasundaram, David Vállez, García, Elisabeth, Pfaehler, Yvonne W S, Jauw, Josée M, Zijlstra, Guus A M S, van Dongen, Willemien C, Menke-van der Houven van Oordt, Marc C, Huisman, Elisabeth G E, de Vries, Ronald, Boellaard
Publikováno v:
EJNMMI physics. 9(1)
Low photon count inCount-splitFor S50p, a total of 92% and 90% features were classified as having good or excellent ICC and SDM respectively, while for S25p, these decreased to 81% and 31%. In total, 148 features (31%) showed robustness to noise with
Autor:
Ramy Sedhom, Mikkjal Skardhamar, Michael A. Carducci, Henk M.W. Verheul, Joeri A. J. Douma, Divya Dharmaraj, Anthony De Felice, Mariette Labots, Laurien M. Buffart, Esther Lee, Willemien C. Menke-van der Houven van Oordt, Nilofer S. Azad
Publikováno v:
Cancers
Volume 13
Issue 10
Cancers, 13, 10
Cancers, Vol 13, Iss 2304, p 2304 (2021)
Cancers, 13(10):2304. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13
Douma, J A J, Buffart, L M, Sedhom, R, Labots, M, Menke-van der Houven van Oordt, W C, Skardhamar, M, de Felice, A, Lee, E, Dharmaraj, D, Azad, N S, Carducci, M A & Verheul, H M W 2021, ' Clinical predictors of early trial discontinuation for patients participating in phase i clinical trials in oncology ', Cancers, vol. 13, no. 10, 2304 . https://doi.org/10.3390/cancers13102304
Volume 13
Issue 10
Cancers, 13, 10
Cancers, Vol 13, Iss 2304, p 2304 (2021)
Cancers, 13(10):2304. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13
Douma, J A J, Buffart, L M, Sedhom, R, Labots, M, Menke-van der Houven van Oordt, W C, Skardhamar, M, de Felice, A, Lee, E, Dharmaraj, D, Azad, N S, Carducci, M A & Verheul, H M W 2021, ' Clinical predictors of early trial discontinuation for patients participating in phase i clinical trials in oncology ', Cancers, vol. 13, no. 10, 2304 . https://doi.org/10.3390/cancers13102304
Despite stringent eligibility criteria for trial participation, early discontinuation often occurs in phase I trials. To better identify patients unlikely to benefit from phase I trials, we investigated predictors for early trial discontinuation. Dat